Mitochondrial markers of neurodegenerative diseases
Disclosed is an in vitro method to diagnose or determine the risk of developing a neurodegenerative disease in a subject based on the determination of the methylation pattern in certain regions of mitochondrial DNA from the subject or the determination of the nucleotide at the polymorphic position 16519 in the mitochondrial DNA of the subject. Also, disclosed are nucleic acids suitable for the in vitro method to diagnose or determine the risk of developing a neurodegenerative disease in a subject.
1. A method for detecting hypermethylation in the D-loop region of mitochondrial DNA comprising:
(a) obtaining a mitochondrial DNA sample comprising SEQ ID NO: 1 from a subject; and
(b) detecting hypermethylation at CpG sites in the D-loop of the mitochondrial DNA,
wherein the CpG sites are selected from the group consisting of CpG sites at positions 16427, 16449, 16454, 16495, 16542, 16565, 61, 162, and 170 of SEQ ID NO: 1;
wherein said detecting is conducted by a technique selected from the group consisting of methylation specific PCR, bisulfite sequencing, techniques based on restriction-digestion, pyrosequencing, assay ChIP-on-chip, differential conversion, differential restriction and differential weight of site(s) methylated.
2. A method of delaying progression of Alzheimer's disease in a subject, comprising:
(a) performing the method of detecting hypermethylation in the D-loop region of mitochondrial DNA according to claim 1 ; and
(b) delivering a treatment for delaying the progression of Alzheimer's disease to the subject, wherein said treatment is administration of a pharmaceutical agent selected from the group consisting of a cholinesterase inhibitor, a cholinesterase antagonist and N-methyl-D-aspartate (NMDA).
3. The method of claim 2 , wherein the treatment comprises administration of a cholinesterase inhibitor selected from the group consisting of donepezil hydrochloride (Arecept), rivastigmine (Exelon) and galantemina (Reminyl).
4. The method according to claim 2 , wherein the subject has been diagnosed with Alzheimer's disease in stage I-II.
5. The method according to claim 2 , further comprising detecting hypomethylation at CpG sites in the ND1 gene of mitochondrial DNA, wherein the CpG sites are selected from CpG sites at positions 3351, 3375, 3379, 3406, 3453, 3549, and 3642 of SEQ ID NO: 1.
6. The method according to claim 2 , further comprising detecting
(i) hypermethylation at CHG sites in the D-loop region of mitochondrial DNA, wherein the CHG sites are selected from CHG sites at positions of 16426, 16453, 16459, 16466, 16479, 16514, 6, 33, 64, 104, 122, 128, 141, and 253 of SEQ ID NO: 1,
(ii) hypermethylation at CHH sites in the D-loop region of mitochondrial DNA, wherein the CHH sites are selected from CHH sites at positions 16419, 16425, 16429, 16439, 16442, 16446, 16451, 16458, 16465, 16478, 16498, 16507, 16511, 16520, 16527, 16536, 16540, 16546, 16549, 16560, 16563, 4, 11, 15, 18, 26, 29, 39, 43, 48, 76, 86, 110, 113, 132, 140, 144, 147, 150, 164, 167, 190, 194, and 198 of SEQ ID NO: 1,
(iii) hypomethylation at CHG sites in the ND1 gene of mitochondrial DNA, wherein the CHG sites are selected from CHG sites at positions 3374, 3435, 3524, 3529, 3589, 3641, and 3657 of SEQ ID NO: 1, or
(iv) hypomethylation at CpG sites in the ND1 gene of mitochondrial DNA, wherein the CpG sites are selected from CpG sites at positions 3351, 3375, 3379, 3406, 3453, 3549, and 3642 of SEQ ID NO: 1.
7. The method according to claim 1 , wherein said detecting hypermethylation at CpG sites in the D-loop of the mitochondrial DNA, comprises detecting hypermethylation at positions 16427, 16449, 16454, 16495, 16542, 16565, 61, 162, and 170 of SEQ ID NO: 1.
8. The method according to claim 1 , further comprising detecting hypermethylation at CpG sites in the ND1 gene of the mitochondrial DNA, wherein the CpG sites are selected from the group consisting of CpG sites at positions 3351, 3375, 3379, 3406, 3453, 3549, and 3642 of SEQ ID NO: 1.
9. The method according to claim 1 , further comprising detecting hypermethylation at CHG sites in the D-loop region of the mitochondrial DNA, wherein the CHG sites are selected from the group consisting of CHG sites at positions 16426, 16453, 16459, 16466, 16479, 16514, 6, 33, 64, 104, 122, 128, 141, and 253 of SEQ ID NO: 1.
10. The method according to claim 1 , further comprising detecting hypermethylation at CHG sites in the ND1 gene of the mitochondrial DNA, wherein the CHG sites are selected from the group consisting of CHG sites at positions 3374, 3435, 3524, 3529, 3589, 3641, and 3657 of SEQ ID NO: 1.
11. The method according to claim 1 , further comprising detecting hypermethylation at CHH sites in the D-loop region of the mitochondrial DNA, wherein the CHH sites are selected from the group consisting of CHH sites at positions 16419, 16425, 16429, 16439, 16442, 16446, 16451, 16458, 16465, 16478, 16498, 16507, 16511, 16520, 16527, 16536, 16540, 16546, 16549, 16560, 16563, 4, 11, 15, 18, 26, 29, 39, 43, 48, 76, 86, 110, 113, 132, 140, 144, 147, 150, 164, 167, 190, 194, 198 of SEQ ID NO: 1.
12. The method of claim 1 , wherein said detecting is conducted by pyrosequencing.
13. The method according to claim 1 , wherein the mitochondrial DNA obtained from the subject is contained in a biofluid or a biopsy of a solid tissue.
14. The method according to claim 13 , wherein said biofluid is a peripheral blood or a cerebrospinal fluid.
15. The method according to claim 13 , wherein said solid tissue is a brain tissue.
16. The method according to claim 1 , wherein step (b) comprises sequencing at least 11,672 reads per D-loop of the mitochondrial DNA.
17. The method according to claim 1 , further comprising detection of:
(i) hypermethylation at CHG sites in the D-loop region of mitochondrial DNA, wherein the CHG sites are selected from CHG sites at positions 16426, 16453, 16459, 16466, 16479, 16514, 6, 33, 64, 104, 122, 128, 141, and 253 of SEQ ID NO: 1;
(ii) hypermethylation at CHH sites in the D-loop region of mitochondrial DNA, wherein the CHH sites are selected from CHH sites at positions 16419, 16425, 16429, 16439, 16442, 16446, 16451, 16458, 16465, 16478, 16498, 16507, 16511, 16520, 16527, 16536, 16540, 16546, 16549, 16560, 16563, 4, 11, 15, 18, 26, 29, 39, 43, 48, 76, 86, 110, 113, 132, 140, 144, 147, 150, 164, 167, 190, 194, 198 of SEQ ID NO: 1;
(iii) hypomethylation at CpG sites in the ND1 gene of mitochondrial DNA, wherein the CpG sites are selected from CpG sites at positions 3351, 3375, 3379, 3406, 3453, 3549, and 3642 of SEQ ID NO: 1;
(iv) hypomethylation at CHG sites in the ND1 gene of mitochondrial DNA, wherein the CHG sites are selected from CHG sites at positions 3374, 3435, 3524, 3529, 3589, 3641, and 3657 of SEQ ID NO: 1;
(v) hypomethylation at CHG sites in the D-loop region of mitochondrial DNA, wherein the CHG sites are selected from CHG sites at positions 16426, 16453, 16459, 16466, 16479, 16514, 6, 33, 64, 104, 122, 128, 141, and 253 of SEQ ID NO: 1; or
(vi) hypomethylation at CHH sites in the D-loop region of mitochondrial DNA, wherein the CHH sites are selected from CHH sites at positions 16419, 16425, 16429, 16439, 16442, 16446, 16451, 16458, 16465, 16478, 16498, 16507, 16511, 16520, 16527, 16536, 16540, 16546, 16549, 16560, 16563, 4, 11, 15, 18, 26, 29, 39, 43, 48, 76, 86, 110, 113, 132, 140, 144, 147, 150, 164, 167, 190, 194, 198 of SEQ ID NO: 1.
18. A method of delaying progression of Parkinson's disease in a subject, comprising:
(a) obtaining a mitochondrial DNA sample comprising SEQ ID NO: 1 from a subject;
(b) detecting hypomethylation at CpG sites in the D-loop of the mitochondrial DNA,
wherein the CpG sites are selected from the group consisting of CpG sites at positions 16427, 16449, 16454, 16495, 16542, 16565, 61, 162, and 170 of SEQ ID NO: 1; and
(c) delivering a treatment for delaying the progression of Parkinson's disease to the subject, wherein said treatment is administration of a pharmaceutical agent selected from the group consisting of L-dopa, an inhibitor of catechol-o-methyl transferase (COMT), an inhibitor of monoamine oxidase B (MAOB) and a dopamine agonist,
wherein said detecting is conducted by a technique selected from the group consisting of methylation specific PCR, bisulfite sequencing, techniques based on restriction-digestion, pyrosequencing, assay ChIP-on-chip, differential conversion, differential restriction and differential weight of site(s) methylated.
19. The method according to claim 18 , wherein the subject has been diagnosed with Parkinson's disease in stage III-V.
20. The method of claim 18 , wherein the treatment comprises administration of an inhibitor of catechol-o-methyl transferase (COMT) selected from the group consisting of tolcapone (Tasmar) and entacapone (Comtan).
21. The method of claim 18 , wherein the treatment comprises administration of an inhibitor of monoamine oxidase B (MAOB) selected from the group consisting of selegiline (Eldepryl) and rasagaline (Azilect).
22. The method of claim 18 , wherein the treatment comprises administration of a dopamine agonist selected from the group consisting of pramipexole, rotigotine and ropinirole.
23. The method of claim 18 , further comprising repeating steps (a) and (b) at a later stage of Parkinson's disease.
24. The method according to claim 18 , further comprising detection of
(i) hypomethylation at CHG sites in the D-loop of mitochondrial DNA, wherein the CHG sites are selected from CHG sites at positions 16426, 16453, 16459, 16466, 16479, 16514, 6, 33, 64, 104, 122, 128, 141, and 253 of SEQ ID NO: 1; and/or
(ii) hypomethylation at CHH sites in the D-loop of mitochondrial DNA, wherein the CHH sites are selected from CHH sites at positions 16419, 16425, 16429, 16439, 16442, 16446, 16451, 16458, 16465, 16478, 16498, 16507, 16511, 16520, 16527, 16536, 16540, 16546, 16549, 16560, 16563, 4, 11, 15, 18, 26, 29, 39, 43, 48, 76, 86, 110, 113, 132, 140, 144, 147, 150, 164, 167, 190, 194, 198 of SEQ ID NO: 1.